Jefferies analyst Roger Song has maintained their bullish stance on UTHR stock, giving a Buy rating today.
Roger Song’s rating is based on United Therapeutics’ strong commercial performance and promising pipeline developments. The company has demonstrated robust growth, particularly with its Tyvaso product, which remains the leading prescribed prostacyclin in the U.S. for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This growth is expected to continue with double-digit year-over-year increases.
Additionally, United Therapeutics is advancing its pipeline with significant upcoming milestones, including the TETON2 and TETON1 trials for idiopathic pulmonary fibrosis, and the Phase 3 trial for Ralinepag in pulmonary arterial hypertension. The company’s strategic initiatives, such as expanding its sales force and launching new products like the next-generation subcutaneous pump, further support its growth trajectory. These factors collectively contribute to Roger Song’s Buy rating for United Therapeutics.
Song covers the Healthcare sector, focusing on stocks such as Kura Oncology, Replimune Group, and Structure Therapeutics, Inc. Sponsored ADR. According to TipRanks, Song has an average return of -22.7% and a 24.43% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $425.00 price target.